causal
Regulatory Arbitrage Steers Investment Toward Cancer and Rare Disease
Because cancers and rare genetic diseases have high unmet need and lower evidence requirements for accelerated approval, companies invest disproportionately there, bypassing large Phase III trials that are needed in conditions with established standards of care like diabetes.
causalpending
Speaker
AlexEvidence Quote
“you've seen a lot of this investment in cancers and rare genetic diseases. The requirement for evidence is lower and the need is greater.”
Source
Alex Telford - Unlocking Innovation in Pharma - [Invest Like the Best, EP.360]— Invest Like the BestCreated: 11/14/2026, 6:42:06 AM
Your notes
Loading notes...